Epcoritamab _ MedChemExpress (MCE)

MCE 国际站：Epcoritamab

参考详情：Epcoritamab (GEN3013，艾可瑞妥单抗) - 仅供科研 | 抗CD3/CD20抗体 | MCE

CAS：2134641-34-0

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Epcoritamab (GEN3013) 是一种双特异性 IgG1 抗体，可将 T 细胞重定向至 CD3×CD20+ 肿瘤细胞。

体外：Epcoritamab (30 ng/mL) 在健康供体外周血单核细胞 (PBMC) 存在的情况下诱导有效的细胞毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

热销产品：Tofacitinib  | Dabrafenib  | Stigmastanol  | O-Propargyl-Puromycin  | JC-1  | Conduritol B epoxide  | Tocilizumab  | Rituximab  | Secukinumab  | sulfo-SPDB-DM4

研究领域：Immunology/Inflammation

作用靶点：CD3  |  CD20

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

参考文献：

[1]. van der Horst HJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021 Feb 18;11(2):38.

[2]. Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247.